placeholder image
J. H. Fischer All authors
About
Publications While At 开云体育
selected publications
Journal Article
  • Phase I dose-escalation study of procaspase-activating compound-1 in combination with temozolomide in patients with recurrent high-grade astrocytomas. 
    Neurooncol Adv. 2023
  • Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies. 
    British Journal of Cancer. 2023
  • The combination of PAC-1 and entrectinib for the treatment of metastatic uveal melanoma. 
    Melanoma Research. 2023
  • Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy. 
    Breast Cancer Research and Treatment. 2020
  • Phase I study of IGF-methotrexate conjugate in the treatment of advanced tumors expressing IGF-1R. 
    American Journal of Clinical Oncology. 2019
  • Phase I study of aurora A kinase inhibitor alisertib (MLN8237) in combination with selective VEGFR inhibitor pazopanib for therapy of advanced solid tumors. 
    American Journal of Clinical Oncology. 2019
  • Phase I study of pazopanib and ixabepilone in patients with solid tumors. 
    American Journal of Clinical Oncology. 2016
    • Contact
    full name
  • J. H. Fischer
    • Quick Info
    Publications
    Publications in the past 10 years based solely on publications while at 开云体育. Publications in prior years appear in grey.
    Collaboration